QRFP receptor in GtoPdb v.2023.1

Authors

  • Didier Bagnol Arena Pharmaceuticals
  • Tom I. Bonner National Institute of Mental Health
  • Myrna Carlebur University of Cambridge
  • Anthony P. Davenport University of Cambridge https://orcid.org/0000-0002-2096-3117
  • Stephen M. Foord GlaxoSmithKline
  • Shoji Fukusumi University of Tsukuba
  • Riccarda Granata University of Torino Medical School
  • Dan Larhammar Uppsala University
  • Jérôme Leprince Normandy University https://orcid.org/0000-0002-7814-9927
  • Janet J. Maguire University of Cambridge https://orcid.org/0000-0002-9254-7040
  • Stefany D. Primeaux Louisiana State University
  • Hubert Vaudry Normandy University

DOI:

https://doi.org/10.2218/gtopdb/F54/2023.1

Abstract

The human gene encoding the QRFP receptor (nomenclature as agreed by the NC-IUPHAR Subcommittee on the QRFP receptor [19]; QRFPR, formerly known as the Peptide P518 receptor), previously designated as an orphan GPCR receptor was identified in 2001 by Lee et al. from a hypothalamus cDNA library [17]. However, the reported cDNA (AF411117) is a chimera with bases 1-127 derived from chromosome 1 and bases 155-1368 derived from chromosome 4. When corrected, QRFPR (also referred to as SP9155 or AQ27) encodes a 431 amino acid protein that shares sequence similarities in the transmembrane spanning regions with other peptide receptors. These include neuropeptide FF2 (38%), neuropeptide Y2 (37%) and galanin Gal1 (35%) receptors. QRFP receptor was identified as a Gs-coupled GPCR [6, 14] that's activated by the endogenous peptides QRFP43 (43RFa) and QRFP26 (26RFa) [6, 14, 11]. However, Gq- and Gi/o-mediated signaling was also reported [11, 25]. Two naturally occurring mutations in the human QRFP receptor lead to distinct and opposite 26RFa-evoked signaling bias [20].

Published

26-Apr-2023

Issue

Section

Summaries

How to Cite

“QRFP receptor in GtoPdb v.2023.1” (2023) IUPHAR/BPS Guide to Pharmacology CITE, 2023(1). doi:10.2218/gtopdb/F54/2023.1.